Search

Displaying results 2541 - 2550 of 10000 in total
  1. Drug

    Fesoterodine

    go.drugbank.com/drugs/DB06702
    Approved

    Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

  2. Drug

    Etoposide

    go.drugbank.com/drugs/DB00773
    ApprovedInvestigational

    Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. … Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

    Products: INJECTION ETOPOSIDE CS 100MG IN 5ML
  3. Drug

    Bismuth subgallate

    go.drugbank.com/drugs/DB13909
    Approved

    Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter … Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight.

  4. Drug

    Creatine

    go.drugbank.com/drugs/DB00148
    ApprovedInvestigationalNutraceutical

    An amino acid derivative that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine.

    Synonyms: N-methyl-N-guanylglycine, N-carbamimidoyl-N-methylglycine
  5. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA). … [L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription.

  6. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.

  7. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    [L4168] It was approved for the same indications in Canada in June 2022. … Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.[A36741]

  8. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … [A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics.

  9. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    [L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib. … To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.

  10. Drug

    Benzonatate

    go.drugbank.com/drugs/DB00868
    Approved

    Benzonatate is an oral antitussive drug used in the relief and suppression of cough in patients older than ten years of age. … Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.

    Synonyms: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate